In cancers that share common chemotherapy regimens with ATC, MDR mechanisms involve overexpression of ABC transporters, contributing to resistance against commonly used drugs like doxorubicin, cisplatin, and paclitaxel, drugs also utilized in ATC treatment [90,91]. The gene discussed is ABCG2; the disease is cancer.